Recommended Articles
Deals & Exits

Private Equity Healthcare Dealmaking Cooled in Q3 2026

By Angeled · October 22, 2026 · Deals & Exits
Private Equity Healthcare Dealmaking Cooled in Q3 2026
Private Equity Healthcare Dealmaking Cooled in Q3 2026

The news

On October 21, 2026, data captured in the LevinPro HC platform showed private equity firms and their portfolio companies announced 135 healthcare M&A transactions in the third quarter of 2026 β€” about 33% of the 415 announced healthcare deals in the quarter. That is down from 155 PE transactions in Q2 2026 and 190 in Q3 2025, a clear deceleration in the sector's most active buyer class.

Disclosed spending totaled nearly $9.14 billion across just 10 deals with a disclosed PE buyer. The largest was KKR's $5.7 billion acquisition of Integer Holdings, the medical-device contract manufacturer. Physician medical groups drew the heaviest PE interest β€” 53 deals, or nearly 40% of PE activity β€” with dental practices alone accounting for 26 announcements. Life sciences R&D was the second-most-active sector with 15 deals, up from 10 in both Q2:26 and Q3:25.

The numbers

The headline decline masks a concentration story. Deal count fell, but the checks that did get written were large: KKR's Integer buyout alone accounted for well over half of disclosed PE healthcare spending in the quarter. Integer β€” one of the world's largest medical-device outsource manufacturers, with $1.85 billion in 2025 revenue and nearly $292.4 million in EBITDA β€” sold at roughly 3x revenue and nearly 20x EBITDA, a multiple that says buyers will still pay up for scale assets with defensible market positions.

The specialty mix is equally telling. Dental (26 deals) and dermatology (7) dominate the physician-practice rollup trade β€” high-volume, cash-pay-adjacent, fragmented specialties where the rollup playbook is well-worn. Eye care and cardiology tied at three deals each. And the life-sciences R&D uptick β€” 15 deals, with contract development and manufacturing organizations (CDMOs) the most active subsector at eight β€” suggests PE is rotating toward the picks-and-shovels of drug development rather than provider businesses facing reimbursement and regulatory scrutiny.

Background and context

Healthcare has been private equity's favorite hunting ground for a decade: aging demographics, fragmented provider markets, and recurring revenue made it the quintessential rollup sector. But the trade has attracted escalating pushback. The FTC under multiple administrations has challenged PE-backed healthcare deals; state legislatures have passed corporate-practice-of-medicine restrictions; and the 2024–2025 wave of headlines about PE-owned hospitals cutting staffing created genuine political risk.

The Q3:26 slowdown likely reflects three forces converging. First, the cost of capital: elevated rates make leveraged rollups of small practices harder to pencil. Second, regulatory friction: antitrust scrutiny of serial acquisitions β€” the FTC's interest in "roll-up" strategies β€” raises the legal cost of every tuck-in. Third, valuation discipline: after years of paying premium multiples for dental and behavioral health platforms, sponsors are discovering that not every rollup integrates, and exits have been slower than the models assumed.

The rotation into life sciences R&D and CDMOs is the tell. Contract manufacturers and clinical-trial operators sell to pharma's R&D budgets β€” which are growing β€” rather than to insurers' reimbursement schedules, which are not. It's the same logic that made picks-and-shovels AI infrastructure the trade of 2024–2026: own the toll road, not the traffic.

Why it matters for founders

If you're building in healthcare, the buyer map just shifted. Provider-rollup exits are cooling while infrastructure exits are heating. A founder with a dental-practice SaaS tool faces a consolidating buyer base with less acquisition appetite; a founder with a CDMO-enabling platform β€” manufacturing automation, trial recruitment, lab informatics β€” is selling into the subsector where PE deal count is actually rising.

The KKR–Integer deal is the template to study: $5.7 billion for a scaled, profitable, defensible manufacturer. PE still pays premium multiples, but only for assets with real scale and real margins. Sub-scale rollups of sub-scale practices are where the 2026 slowdown bites hardest.

Why it matters for investors

For private investors, the data argues for a barbell: large platform assets (Integer-style) where sponsors will pay 20x EBITDA, and infrastructure/R&D services where deal flow is growing. The middle β€” small provider rollups at 2021 multiples β€” is where the Q3 decline is concentrated, and where exit timelines are extending.

For public investors, KKR's Integer acquisition is the comp to watch: it reprices every public medical-device contract manufacturer and life-sciences tools company upward. And the CDMO subsector's eight deals in a single quarter suggest the public life-sciences tools names β€” the Danahers and Thermo Fishers of the world β€” are operating in a market where private buyers are actively validating their multiples.

Angeled.com connects founders with investors.

Read Next